Crescent Biopharma

1. CR-001 + ADC combination trial2H 2026CR-001 + ADC combination trial, 2H 2026, notable
2. CR-002 Ph1 start2H 2026CR-002 Ph1 start, 2H 2026, routine
3. CR-001 Ph1 topline1Q 2027CR-001 Ph1 topline, 1Q 2027, thesis-defining
4. CR-001 topline1Q 2027CR-001 topline, 1Q 2027, major
5. CR-003 / SKB105 Ph1 readout1Q 2027CR-003 / SKB105 Ph1 readout, 1Q 2027, material
6. CR-001 + Kelun-Biotech ADCs combinationmid-2027CR-001 + Kelun-Biotech ADCs combination, mid-2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.